All In Biotech

Drug Trial Radar · NCT00611026

Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine Extended Release(ER)in Patients With Overactive Bladder.

12-Week, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Multicenter Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Comparison To Tolterodine ER In Patients With Overactive Bladder.

Last checked: Nov 20, 2026Latest source record: Feb 2, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 2,417 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,417

Actual

Start

Feb 2008

Primary completion

Oct 2009

Study completion Oct 2009

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Feb 8, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the efficacy and safety of fesoterodine in comparison to tolterodine and placebo for overactive bladder

Conditions

  • Overactive Bladder

Interventions

  • Tolterodine ERDrug

    The tolterodine treatment will be 4 mg once daily(QD) for 12 weeks.

  • PlaceboDrug

    Placebo treatment will be once daily(QD) for 12 weeks.

  • FesoterodineDrug

    The fesoterodine treatment will start with 4 mg once daily(QD) for 1 week followed by a forced dose-escalation to 8mg once daily(QD) for 11 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Week 12Time frame: Baseline, Week 12

Locations

227 sites in 25 countries. Site status is shown where the registry gives one.

  • Pfizer Investigational Site

    Enterprise, Alabama

  • Pfizer Investigational Site

    Mobile, Alabama

  • Pfizer Investigational Site

    Montgomery, Alabama

  • Pfizer Investigational Site

    Chandler, Arizona

  • Pfizer Investigational Site

    Peoria, Arizona

  • Pfizer Investigational Site

    Tucson, Arizona

  • Pfizer Investigational Site

    Little Rock, Arkansas

  • Pfizer Investigational Site

    Anaheim, California

  • Pfizer Investigational Site

    Clovis, California

  • Pfizer Investigational Site

    Fresno, California

  • Pfizer Investigational Site

    Fresno, California

  • Pfizer Investigational Site

    San Diego, California

  • Pfizer Investigational Site

    Torrance, California

  • Pfizer Investigational Site

    Upland, California

  • Pfizer Investigational Site

    Vista, California

  • Pfizer Investigational Site

    Westlake Village, California

  • Pfizer Investigational Site

    Englewood, Colorado

  • Pfizer Investigational Site

    New London, Connecticut

  • Pfizer Investigational Site

    Bonita Spring, Florida

  • Pfizer Investigational Site

    Hollywood, Florida

  • Pfizer Investigational Site

    Jacksonville, Florida

  • Pfizer Investigational Site

    Jacksonville, Florida

  • Pfizer Investigational Site

    Lake Worth, Florida

  • Pfizer Investigational Site

    Leesburg, Florida

  • Pfizer Investigational Site

    Longwood, Florida

  • Pfizer Investigational Site

    Loxahatchee Groves, Florida

  • Pfizer Investigational Site

    Miami, Florida

  • Pfizer Investigational Site

    Miami, Florida

  • Pfizer Investigational Site

    Naples, Florida

  • Pfizer Investigational Site

    Pembroke Pines, Florida

  • Pfizer Investigational Site

    Stuart, Florida

  • Pfizer Investigational Site

    Tallahassee, Florida

  • Pfizer Investigational Site

    West Palm Beach, Florida

  • Pfizer Investigational Site

    Atlanta, Georgia

  • Pfizer Investigational Site

    Atlanta, Georgia

  • Pfizer Investigational Site

    Meridian, Idaho

  • Pfizer Investigational Site

    Chicago, Illinois

  • Pfizer Investigational Site

    Peoria, Illinois

  • Pfizer Investigational Site

    Avon, Indiana

  • Pfizer Investigational Site

    Evansville, Indiana

Showing 40 of 227 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.